1.74 USD
-0.02 (-1.14%)
We assign a fundamental rating of 3 out of 10 to INMB. INMB was compared to 534 industry peers in the Biotechnology industry. The financial health of INMB is average, but there are quite some concerns on its profitability. INMB is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
INMB had negative earnings in the past year.
In the past year INMB has reported a negative cash flow from operations.
INMB had negative earnings in each of the past 5 years.
In the past 5 years INMB always reported negative operating cash flow.
1.2 Ratios
INMB's Return On Assets of -149.55% is on the low side compared to the rest of the industry. INMB is outperformed by 84.83% of its industry peers.
INMB has a worse Return On Equity (-196.58%) than 66.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -149.55% | ||
| ROE | -196.58% | ||
| ROIC | N/A |
ROA(3y)-64.13%
ROA(5y)-50.5%
ROE(3y)-85.07%
ROE(5y)-64.85%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
INMB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, INMB has more shares outstanding
The number of shares outstanding for INMB has been increased compared to 5 years ago.
There is no outstanding debt for INMB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -7.64, we must say that INMB is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of INMB (-7.64) is worse than 68.35% of its industry peers.
INMB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -7.64 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 4.17 indicates that INMB has no problem at all paying its short term obligations.
With a Current ratio value of 4.17, INMB perfoms like the industry average, outperforming 49.81% of the companies in the same industry.
INMB has a Quick Ratio of 4.17. This indicates that INMB is financially healthy and has no problem in meeting its short term obligations.
INMB has a Quick ratio of 4.17. This is comparable to the rest of the industry: INMB outperforms 50.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.17 | ||
| Quick Ratio | 4.17 |
3. Growth
3.1 Past
INMB shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.75%.
The Revenue has grown by 19.05% in the past year. This is quite good.
INMB shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -57.31% yearly.
EPS 1Y (TTM)2.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
Revenue 1Y (TTM)19.05%
Revenue growth 3Y-57.31%
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
INMB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.69% yearly.
Based on estimates for the next years, INMB will show a very strong growth in Revenue. The Revenue will grow by 496.62% on average per year.
EPS Next Y24.88%
EPS Next 2Y14.68%
EPS Next 3Y12.2%
EPS Next 5Y15.69%
Revenue Next Year280.95%
Revenue Next 2Y2073.39%
Revenue Next 3Y798.36%
Revenue Next 5Y496.62%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
INMB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INMB. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
INMB's earnings are expected to grow with 12.20% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.68%
EPS Next 3Y12.2%
5. Dividend
5.1 Amount
No dividends for INMB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:INMB (12/4/2025, 9:40:49 AM)
1.74
-0.02 (-1.14%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners21.07%
Inst Owner Change-18.33%
Ins Owners17.52%
Ins Owner Change0%
Market Cap46.27M
Revenue(TTM)50.00K
Net Income(TTM)-49.89M
Analysts76.67
Price Target8.57 (392.53%)
Short Float %15.65%
Short Ratio9
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-71.06%
Min EPS beat(2)-169.71%
Max EPS beat(2)27.6%
EPS beat(4)3
Avg EPS beat(4)-26.11%
Min EPS beat(4)-169.71%
Max EPS beat(4)27.6%
EPS beat(8)4
Avg EPS beat(8)-14.65%
EPS beat(12)6
Avg EPS beat(12)-146.22%
EPS beat(16)10
Avg EPS beat(16)-103.87%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)11.67%
EPS NQ rev (3m)11.67%
EPS NY rev (1m)0%
EPS NY rev (3m)-5.89%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-20%
Revenue NY rev (3m)20.01%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 925.33 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.82 | ||
| P/tB | 1.82 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.12
EYN/A
EPS(NY)-1.45
Fwd EYN/A
FCF(TTM)-1.2
FCFYN/A
OCF(TTM)-1.17
OCFYN/A
SpS0
BVpS0.95
TBVpS0.95
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -149.55% | ||
| ROE | -196.58% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-64.13%
ROA(5y)-50.5%
ROE(3y)-85.07%
ROE(5y)-64.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.17 | ||
| Quick Ratio | 4.17 | ||
| Altman-Z | -7.64 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
EPS Next Y24.88%
EPS Next 2Y14.68%
EPS Next 3Y12.2%
EPS Next 5Y15.69%
Revenue 1Y (TTM)19.05%
Revenue growth 3Y-57.31%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year280.95%
Revenue Next 2Y2073.39%
Revenue Next 3Y798.36%
Revenue Next 5Y496.62%
EBIT growth 1Y15.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-123.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-117.08%
OCF growth 3YN/A
OCF growth 5YN/A
INMUNE BIO INC / INMB FAQ
What is the ChartMill fundamental rating of INMUNE BIO INC (INMB) stock?
ChartMill assigns a fundamental rating of 3 / 10 to INMB.
Can you provide the valuation status for INMUNE BIO INC?
ChartMill assigns a valuation rating of 0 / 10 to INMUNE BIO INC (INMB). This can be considered as Overvalued.
How profitable is INMUNE BIO INC (INMB) stock?
INMUNE BIO INC (INMB) has a profitability rating of 0 / 10.
Can you provide the financial health for INMB stock?
The financial health rating of INMUNE BIO INC (INMB) is 6 / 10.
Can you provide the expected EPS growth for INMB stock?
The Earnings per Share (EPS) of INMUNE BIO INC (INMB) is expected to grow by 24.88% in the next year.